TLR activation and ionizing radiation induce strong immune responses against multiple tumor entities

OncoImmunology

Volumn 4, Issue 11, 2015, Pages

  Schölch, Sebastian ^a,b   Rauber, Conrad ^c   Weitz, Jürgen ^a   Koch, Moritz ^a   Huber, Peter E ^b,c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

colorectal cancer; GI tumors; immunotherapy; pancreatic cancer; radiotherapy; TLR7 8 ligand; Toll like receptor

Indexed keywords

TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; COLORECTAL CANCER; DOWN REGULATION; GASTROINTESTINAL TUMOR; HUMAN; IMMUNE RESPONSE; IONIZING RADIATION; NEOPLASM; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84941790061     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1042201     Document Type: Article

References (10)

1. R.M.Steinman, J.Banchereau. Taking dendritic cells into medicine. Nature 2007; 449:419-26; PMID:17898760; http://dx.doi.org/10.1038/nature06175
2. E.Vacchelli, I.Vitale, E.Tartour, A.Eggermont, C.Sautès-Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology 2013; 2:e25595; PMID:24319634; http://dx.doi.org/10.4161/onci.25595
3. +/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 2013; 24:589-602; PMID:24209604; http://dx.doi.org/10.1016/j.ccr.2013.09.014
4. G.Kroemer, L.Zitvogel. Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy. Oncoimmunology 2012; 1:407-8; PMID:22754758; http://dx.doi.org/10.4161/onci.20074
5. S.Schölch, C.Rauber, A.Tietz, N.N.Rahbari, U.Bork, T.Schmidt, C.Kahlert, U.Haberkorn, M.A.Tomai, K.E.Lipson, et al. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors. Oncotarget 2015; 6:4663-76
6. S.J.Dovedi, M.H.M.Melis, R.W.Wilkinson, A.L.Adlard, I.J.Stratford, J.Honeychurch, T.M.Illidge. Systemic delivery of a TLR7 agonist in combination with radiation primes durable anti-tumor immune responses in mouse models of lymphoma. 2013; 121:251–9; http://dx.doi.org/10.1182/blood-2012-05-432393
7. A.L.Adlard, S.J.Dovedi, B.A.Telfer, E.Koga-Yamakawa, C.Pollard, J.Honeychurch, T.M.Illidge, M.Murata, D.T.Robinson, P.J.Jewsbury, et al. A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. Int J Cancer 2014; 135(4):820-9; PMID:24390981
8. N.J.Horscroft, D.C.Pryde, H.Bright. Antiviral applications of Toll-like receptor agonists. J Antimicrob Chemother 2012; 67:789-801; PMID:22258929; http://dx.doi.org/10.1093/jac/dkr588
9. F.Bath-Hextall, M.Ozolins, S.J.Armstrong, G.B.Colver, W.Perkins,P.S.J.Miller, H.C.Williams, Surgery versus Imiquimod for Nodular Superficial basal cell carcinoma (SINS) study group. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol 2014; 15:96-105; PMID:24332516; http://dx.doi.org/10.1016/S1470-2045(13)70530-8
10. M.F.Naylor, W.R.Chen, T.K.Teague, L.A.Perry, R.E.Nordquist. In situ photoimmunotherapy: a tumour-directed treatment for melanoma. Br J Dermatol 2006; 155:1287-92; PMID:17107404; http://dx.doi.org/10.1111/j.1365-2133.2006.07514.x